Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

Market Cap	697.24B
Revenue (ttm)	10.71B
Net Income (ttm)	-14.25B
Shares Out	48.02M
EPS (ttm)	-349.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	824,402
Average Volume	1,003,987
Open	14,150
Previous Close	14,020
Day's Range	13,930 - 14,620
52-Week Range	8,650 - 22,700
Beta	0.88
RSI	77.26
Earnings Date	Aug 14, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 54
• Stock Exchange: KOSDAQ
• Ticker Symbol: 048410

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.